{"gene":"MORC4","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":2020,"finding":"MORC4 has intrinsic ATPase activity that is dependent on DNA-binding functions of both its ATPase domain and CW domain; the crystal structure of the ATPaseCW cassette reveals that the DNA-binding site and histone/ATPase-binding site of the CW domain are on opposite sides of the domain. MORC4 ATPase and CW domains cooperate in binding to the nucleosome core particle (NCP), enhancing DNA wrapping around the histone core and impeding binding of DNA-associated proteins (e.g., transcription factors) to the NCP.","method":"Enzymatic ATPase assays, binding assays, crystal structure determination, mutagenesis studies, nucleosome core particle binding assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure combined with in vitro enzymatic assays, mutagenesis, and NCP binding assays in a single rigorous study","pmids":["33122719"],"is_preprint":false},{"year":2020,"finding":"In cells, MORC4 mediates formation of nuclear bodies in the nucleus and has a role in S-phase progression; both functions require the CW domain and catalytic ATPase activity of MORC4.","method":"Cell-based assays with CW domain mutants and catalytic mutants; nuclear body formation imaging; cell cycle analysis","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct loss-of-function mutagenesis with defined cellular phenotypes (nuclear body formation, S-phase progression) in single rigorous study with multiple orthogonal approaches","pmids":["33122719"],"is_preprint":false},{"year":2020,"finding":"MORC4 interacts with STAT3 (confirmed by co-immunoprecipitation), and MORC4 promotes transcriptional activation of MID2 via STAT3-binding sites in the MID2 promoter (confirmed by ChIP-qPCR and dual-luciferase assay), thereby increasing chemoresistance in luminal A/B breast cancer cells.","method":"Co-immunoprecipitation (Co-IP), ChIP-qPCR, dual-luciferase reporter assay, siRNA knockdown, overexpression experiments","journal":"OncoTargets and therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP plus ChIP-qPCR and reporter assay, single lab","pmids":["32764967"],"is_preprint":false},{"year":2023,"finding":"MORC4 physically interacts with PCGF1 (a transcriptional repressor of CDKN1A/p21), as confirmed by co-immunoprecipitation; MORC4 itself does not substantially suppress CDKN1A transcription but augments PCGF1's repressive effect on CDKN1A, promoting colorectal cancer cell proliferation and metastasis.","method":"Co-immunoprecipitation, siRNA knockdown of PCGF1, overexpression experiments, in vitro and in vivo tumor assays","journal":"Cancer gene therapy","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single Co-IP with functional follow-up (knockdown rescue), single lab","pmids":["36932196"],"is_preprint":false},{"year":2023,"finding":"MORC4 protein is a substrate of the E3 ubiquitin ligase HECW2 and is degraded through the ubiquitin-proteasome system.","method":"Co-immunoprecipitation, proteasome inhibitor experiments (inferred from abstract description of MORC4 as HECW2 substrate degraded via ubiquitin-proteasome system)","journal":"Cancer gene therapy","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, single method (Co-IP), limited mechanistic detail available in abstract","pmids":["36932196"],"is_preprint":false},{"year":2018,"finding":"miR-193b-3p directly binds the 3' UTR of MORC4 mRNA (confirmed by dual-luciferase reporter assay) and negatively regulates MORC4 protein levels in breast cancer cells; MORC4 silencing promotes apoptosis and suppresses breast cancer cell growth.","method":"Dual-luciferase reporter assay, siRNA knockdown, miRNA overexpression, Western blot, qRT-PCR","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter assay plus loss-of-function experiments, single lab, two orthogonal methods","pmids":["30320920"],"is_preprint":false},{"year":2019,"finding":"miR-338-3p directly targets MORC4 (confirmed by luciferase reporter assay and RNA immunoprecipitation); MORC4 overexpression rescues the suppressive effects of miR-338-3p on breast cancer cell viability, migration, and invasion.","method":"Luciferase reporter assay, RNA immunoprecipitation (RIP), siRNA/overexpression experiments, MTT assay, transwell assay","journal":"OncoTargets and therapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter plus RIP, single lab, two orthogonal methods","pmids":["31908485"],"is_preprint":false},{"year":2007,"finding":"MORC4 protein contains a HATPase-c domain, CW zinc finger motif, nuclear localization signals, a nuclear matrix-binding domain, and a coiled-coil region, consistent with nuclear localization and chromatin-associated function.","method":"Gene/protein domain analysis and expression characterization; antibody-based detection in DLBCL patient samples","journal":"British journal of haematology","confidence":"Low","confidence_rationale":"Tier 4 / Weak — domain annotation without functional validation experiments; no direct biochemical or cellular mechanistic assay reported","pmids":["17608765"],"is_preprint":false},{"year":2025,"finding":"MORC4 knockdown in hepatocytes elevates total cholesterol and triglyceride levels and increases lipid accumulation, associated with increased expression of cholesterol synthesis gene HMGCR and altered expression of fatty acid/cholesterol uptake genes (PCSK9, PLTP, CD36) and decreased triglyceride hydrolysis genes (APOC2, APOA4, LIPG, LIPA); MORC4 overexpression reverses these effects, identifying MORC4 as a regulator of hepatic lipid metabolism.","method":"siRNA knockdown and overexpression in hepatocytes, TC/TG measurement, lipid accumulation assay, gene expression analysis; in vivo Morc4 knockout mouse data from IMPC database","journal":"Frontiers in cardiovascular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function experiments with defined metabolic phenotypes and gene expression readouts, single lab","pmids":["40606021"],"is_preprint":false}],"current_model":"MORC4 is a nuclear chromatin-associated ATPase whose activity is activated by cooperative DNA-binding via its ATPase and CW domains; it binds nucleosome core particles to enhance DNA wrapping and impede transcription factor access, forms nuclear bodies, promotes S-phase progression, interacts with STAT3 to transcriptionally activate MID2, interacts with PCGF1 to repress CDKN1A, is targeted for proteasomal degradation by the E3 ligase HECW2, is post-transcriptionally repressed by miR-193b-3p and miR-338-3p, and regulates hepatic lipid metabolism including cholesterol and triglyceride homeostasis."},"narrative":{"mechanistic_narrative":"MORC4 is a nuclear, chromatin-associated ATPase that modulates nucleosome architecture and gene accessibility [PMID:33122719, PMID:17608765]. Its ATPase activity depends on cooperative DNA binding by both its ATPase domain and its CW zinc-finger domain, which together engage the nucleosome core particle to enhance DNA wrapping around the histone core and impede access of DNA-binding proteins such as transcription factors [PMID:33122719]. In cells, both the CW domain and catalytic ATPase activity are required for MORC4 to form nuclear bodies and to support S-phase progression [PMID:33122719]. MORC4 also engages specific transcriptional partners to shape gene expression: it interacts with STAT3 to activate transcription of MID2 through STAT3 sites in the MID2 promoter [PMID:32764967], and it physically associates with the repressor PCGF1 to augment repression of the cell-cycle inhibitor CDKN1A, promoting proliferation [PMID:36932196]. MORC4 protein abundance is controlled at multiple levels — by proteasomal degradation through the E3 ligase HECW2 [PMID:36932196] and by post-transcriptional repression via miR-193b-3p and miR-338-3p binding its 3' UTR [PMID:30320920, PMID:31908485]. Beyond the nucleus, loss-of-function and gain-of-function studies in hepatocytes identify MORC4 as a regulator of hepatic lipid metabolism, controlling cholesterol and triglyceride homeostasis and the expression of lipid synthesis, uptake, and hydrolysis genes [PMID:40606021].","teleology":[{"year":2007,"claim":"Established the domain architecture predicting MORC4 as a nuclear chromatin-associated protein, providing the structural rationale that later biochemical work would test.","evidence":"Protein domain annotation and antibody detection in DLBCL patient samples","pmids":["17608765"],"confidence":"Low","gaps":["Domain annotation without functional validation","No direct biochemical or cellular assay of any predicted activity"]},{"year":2018,"claim":"Showed MORC4 abundance is post-transcriptionally controlled by a miRNA and that this loop is functionally consequential for cancer cell survival, answering how MORC4 levels are tuned.","evidence":"Dual-luciferase 3' UTR reporter, miRNA overexpression, and siRNA knockdown in breast cancer cells","pmids":["30320920"],"confidence":"Medium","gaps":["Mechanism linking MORC4 level to apoptosis not defined","Single cancer context"]},{"year":2019,"claim":"Confirmed a second miRNA (miR-338-3p) directly targets MORC4 and that MORC4 mediates its phenotypic effects, reinforcing miRNA-based control of MORC4.","evidence":"Luciferase reporter, RNA immunoprecipitation, and rescue experiments in breast cancer cells","pmids":["31908485"],"confidence":"Medium","gaps":["Downstream molecular pathway from MORC4 to migration/invasion unresolved"]},{"year":2020,"claim":"Defined the core biochemical mechanism: how MORC4 ATPase activity is activated and how the protein remodels nucleosome accessibility, the central molecular function question.","evidence":"Crystal structure of the ATPase-CW cassette plus ATPase assays, mutagenesis, and nucleosome core particle binding assays","pmids":["33122719"],"confidence":"High","gaps":["Genomic targets of nucleosome engagement in vivo not mapped","Connection between in vitro NCP binding and specific gene programs not established"]},{"year":2020,"claim":"Linked MORC4 catalytic and CW-domain functions to cellular outcomes (nuclear body formation, S-phase progression), connecting biochemistry to cell physiology.","evidence":"CW and catalytic mutant cell-based assays, nuclear body imaging, cell cycle analysis","pmids":["33122719"],"confidence":"High","gaps":["Composition and function of MORC4 nuclear bodies undefined","Mechanism linking ATPase activity to S-phase progression unknown"]},{"year":2020,"claim":"Identified a sequence-specific transcriptional output: MORC4 cooperates with STAT3 to activate MID2, showing MORC4 can promote gene expression in a partner-dependent manner.","evidence":"Reciprocal Co-IP, ChIP-qPCR, dual-luciferase reporter, knockdown/overexpression in breast cancer cells","pmids":["32764967"],"confidence":"Medium","gaps":["Whether activation requires MORC4 ATPase/chromatin activity not tested","Single lab"]},{"year":2023,"claim":"Revealed a repressive transcriptional role via PCGF1, showing MORC4 acts as a cofactor that augments repression of CDKN1A rather than repressing it alone.","evidence":"Co-IP, PCGF1 knockdown, overexpression, in vitro and in vivo tumor assays","pmids":["36932196"],"confidence":"Medium","gaps":["Direct chromatin occupancy at CDKN1A not shown","Single Co-IP for interaction"]},{"year":2023,"claim":"Identified HECW2 as the E3 ligase targeting MORC4 for proteasomal degradation, defining a protein-stability control point.","evidence":"Co-IP and proteasome inhibitor experiments (inferred from abstract)","pmids":["36932196"],"confidence":"Low","gaps":["Limited mechanistic detail from abstract","Ubiquitination sites and conditions regulating degradation not defined"]},{"year":2025,"claim":"Extended MORC4 function beyond cancer to hepatic lipid metabolism, showing it regulates cholesterol/triglyceride homeostasis and lipid gene expression.","evidence":"siRNA knockdown and overexpression in hepatocytes, TC/TG and lipid accumulation assays, gene expression analysis, IMPC knockout mouse data","pmids":["40606021"],"confidence":"Medium","gaps":["Whether metabolic effects are direct chromatin-mediated transcriptional regulation not established","Single lab"]},{"year":null,"claim":"How MORC4's in vitro nucleosome-remodeling and ATPase activity connects to its specific transcriptional partnerships (STAT3, PCGF1) and metabolic functions remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No genome-wide map of MORC4 chromatin occupancy","Unknown whether catalytic activity is required for partner-specific transcriptional outputs","Composition of MORC4 nuclear bodies undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,3]},{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[1,7]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[0]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[1,3]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[8]}],"complexes":[],"partners":["STAT3","PCGF1","HECW2"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8TE76","full_name":"MORC family CW-type zinc finger protein 4","aliases":["Zinc finger CW-type coiled-coil domain protein 2","Zinc finger CW-type domain protein 4"],"length_aa":937,"mass_kda":106.3,"function":"Histone methylation reader which binds to non-methylated (H3K4me0), monomethylated (H3K4me1), dimethylated (H3K4me2) and trimethylated (H3K4me3) 'Lys-4' on histone H3 (PubMed:26933034). The order of binding preference is H3K4me3 > H3K4me2 > H3K4me1 > H3K4me0 (PubMed:26933034)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8TE76/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MORC4","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MORC4","total_profiled":1310},"omim":[{"mim_id":"300970","title":"MORC FAMILY CW-TYPE ZINC FINGER PROTEIN 4; MORC4","url":"https://www.omim.org/entry/300970"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"placenta","ntpm":74.7}],"url":"https://www.proteinatlas.org/search/MORC4"},"hgnc":{"alias_symbol":["ZCW4","FLJ11565"],"prev_symbol":["ZCWCC2"]},"alphafold":{"accession":"Q8TE76","domains":[{"cath_id":"3.30.565","chopping":"38-248_262-275","consensus_level":"high","plddt":91.8437,"start":38,"end":275},{"cath_id":"3.30.230.10","chopping":"301-407","consensus_level":"medium","plddt":91.5331,"start":301,"end":407},{"cath_id":"3.30.40.100","chopping":"425-470","consensus_level":"medium","plddt":89.8415,"start":425,"end":470},{"cath_id":"1.10.287","chopping":"771-878","consensus_level":"high","plddt":75.7275,"start":771,"end":878},{"cath_id":"1.10.8","chopping":"883-934","consensus_level":"high","plddt":82.6285,"start":883,"end":934}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TE76","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TE76-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8TE76-F1-predicted_aligned_error_v6.png","plddt_mean":67.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MORC4","jax_strain_url":"https://www.jax.org/strain/search?query=MORC4"},"sequence":{"accession":"Q8TE76","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8TE76.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8TE76/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8TE76"}},"corpus_meta":[{"pmid":"25253127","id":"PMC_25253127","title":"Polymorphisms at PRSS1-PRSS2 and CLDN2-MORC4 loci associate with alcoholic and non-alcoholic chronic pancreatitis in a European replication study.","date":"2014","source":"Gut","url":"https://pubmed.ncbi.nlm.nih.gov/25253127","citation_count":85,"is_preprint":false},{"pmid":"31908485","id":"PMC_31908485","title":"Baicalin Inhibits Cell Viability, Migration and Invasion in Breast Cancer by Regulating miR-338-3p and MORC4.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31908485","citation_count":41,"is_preprint":false},{"pmid":"30320920","id":"PMC_30320920","title":"MORC4 is a novel breast cancer oncogene regulated by miR-193b-3p.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30320920","citation_count":34,"is_preprint":false},{"pmid":"17608765","id":"PMC_17608765","title":"MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.","date":"2007","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/17608765","citation_count":33,"is_preprint":false},{"pmid":"26820620","id":"PMC_26820620","title":"Common Variants in CLDN2 and MORC4 Genes Confer Disease Susceptibility in Patients with Chronic Pancreatitis.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26820620","citation_count":27,"is_preprint":false},{"pmid":"32764967","id":"PMC_32764967","title":"MORC4 Promotes Chemoresistance of Luminal A/B Breast Cancer via STAT3-Mediated MID2 Upregulation.","date":"2020","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32764967","citation_count":21,"is_preprint":false},{"pmid":"33122719","id":"PMC_33122719","title":"Molecular mechanism of the MORC4 ATPase activation.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/33122719","citation_count":20,"is_preprint":false},{"pmid":"26784911","id":"PMC_26784911","title":"Association Analysis of PRSS1-PRSS2 and CLDN2-MORC4 Variants in Nonalcoholic Chronic Pancreatitis Using Tropical Calcific Pancreatitis as Model.","date":"2016","source":"Pancreas","url":"https://pubmed.ncbi.nlm.nih.gov/26784911","citation_count":13,"is_preprint":false},{"pmid":"26827181","id":"PMC_26827181","title":"Single Nucleotide Polymorphisms in MORC4, CD14, and TLR4 Are Related to Outcome of Allogeneic Stem Cell Transplantation.","date":"2016","source":"Annals of transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/26827181","citation_count":9,"is_preprint":false},{"pmid":"36932196","id":"PMC_36932196","title":"MORC4 plays a tumor-promoting role in colorectal cancer via regulating PCGF1/CDKN1A axis in vitro and in vivo.","date":"2023","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/36932196","citation_count":7,"is_preprint":false},{"pmid":"39256868","id":"PMC_39256868","title":"Exosome-mediated transfer of lncRNA RP3-340B19.3 promotes the progression of breast cancer by sponging miR-4510/MORC4 axis.","date":"2024","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/39256868","citation_count":4,"is_preprint":false},{"pmid":"30865939","id":"PMC_30865939","title":"Spatial and temporal resolution of mORC4 fluorescent variants reveals structural requirements for achieving higher order self-association and pronuclei entry.","date":"2019","source":"Methods and applications in fluorescence","url":"https://pubmed.ncbi.nlm.nih.gov/30865939","citation_count":3,"is_preprint":false},{"pmid":"40606021","id":"PMC_40606021","title":"Morc4 is a novel functional gene associated with lipid metabolism in BXD recombinant inbred population.","date":"2025","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40606021","citation_count":1,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9809,"output_tokens":2218,"usd":0.031349,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":9276,"output_tokens":3010,"usd":0.060815,"stage2_stop_reason":"end_turn"},"total_usd":0.092164,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2020,\n      \"finding\": \"MORC4 has intrinsic ATPase activity that is dependent on DNA-binding functions of both its ATPase domain and CW domain; the crystal structure of the ATPaseCW cassette reveals that the DNA-binding site and histone/ATPase-binding site of the CW domain are on opposite sides of the domain. MORC4 ATPase and CW domains cooperate in binding to the nucleosome core particle (NCP), enhancing DNA wrapping around the histone core and impeding binding of DNA-associated proteins (e.g., transcription factors) to the NCP.\",\n      \"method\": \"Enzymatic ATPase assays, binding assays, crystal structure determination, mutagenesis studies, nucleosome core particle binding assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure combined with in vitro enzymatic assays, mutagenesis, and NCP binding assays in a single rigorous study\",\n      \"pmids\": [\"33122719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In cells, MORC4 mediates formation of nuclear bodies in the nucleus and has a role in S-phase progression; both functions require the CW domain and catalytic ATPase activity of MORC4.\",\n      \"method\": \"Cell-based assays with CW domain mutants and catalytic mutants; nuclear body formation imaging; cell cycle analysis\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct loss-of-function mutagenesis with defined cellular phenotypes (nuclear body formation, S-phase progression) in single rigorous study with multiple orthogonal approaches\",\n      \"pmids\": [\"33122719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MORC4 interacts with STAT3 (confirmed by co-immunoprecipitation), and MORC4 promotes transcriptional activation of MID2 via STAT3-binding sites in the MID2 promoter (confirmed by ChIP-qPCR and dual-luciferase assay), thereby increasing chemoresistance in luminal A/B breast cancer cells.\",\n      \"method\": \"Co-immunoprecipitation (Co-IP), ChIP-qPCR, dual-luciferase reporter assay, siRNA knockdown, overexpression experiments\",\n      \"journal\": \"OncoTargets and therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP plus ChIP-qPCR and reporter assay, single lab\",\n      \"pmids\": [\"32764967\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MORC4 physically interacts with PCGF1 (a transcriptional repressor of CDKN1A/p21), as confirmed by co-immunoprecipitation; MORC4 itself does not substantially suppress CDKN1A transcription but augments PCGF1's repressive effect on CDKN1A, promoting colorectal cancer cell proliferation and metastasis.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown of PCGF1, overexpression experiments, in vitro and in vivo tumor assays\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single Co-IP with functional follow-up (knockdown rescue), single lab\",\n      \"pmids\": [\"36932196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MORC4 protein is a substrate of the E3 ubiquitin ligase HECW2 and is degraded through the ubiquitin-proteasome system.\",\n      \"method\": \"Co-immunoprecipitation, proteasome inhibitor experiments (inferred from abstract description of MORC4 as HECW2 substrate degraded via ubiquitin-proteasome system)\",\n      \"journal\": \"Cancer gene therapy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, single method (Co-IP), limited mechanistic detail available in abstract\",\n      \"pmids\": [\"36932196\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"miR-193b-3p directly binds the 3' UTR of MORC4 mRNA (confirmed by dual-luciferase reporter assay) and negatively regulates MORC4 protein levels in breast cancer cells; MORC4 silencing promotes apoptosis and suppresses breast cancer cell growth.\",\n      \"method\": \"Dual-luciferase reporter assay, siRNA knockdown, miRNA overexpression, Western blot, qRT-PCR\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter assay plus loss-of-function experiments, single lab, two orthogonal methods\",\n      \"pmids\": [\"30320920\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-338-3p directly targets MORC4 (confirmed by luciferase reporter assay and RNA immunoprecipitation); MORC4 overexpression rescues the suppressive effects of miR-338-3p on breast cancer cell viability, migration, and invasion.\",\n      \"method\": \"Luciferase reporter assay, RNA immunoprecipitation (RIP), siRNA/overexpression experiments, MTT assay, transwell assay\",\n      \"journal\": \"OncoTargets and therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter plus RIP, single lab, two orthogonal methods\",\n      \"pmids\": [\"31908485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"MORC4 protein contains a HATPase-c domain, CW zinc finger motif, nuclear localization signals, a nuclear matrix-binding domain, and a coiled-coil region, consistent with nuclear localization and chromatin-associated function.\",\n      \"method\": \"Gene/protein domain analysis and expression characterization; antibody-based detection in DLBCL patient samples\",\n      \"journal\": \"British journal of haematology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 / Weak — domain annotation without functional validation experiments; no direct biochemical or cellular mechanistic assay reported\",\n      \"pmids\": [\"17608765\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"MORC4 knockdown in hepatocytes elevates total cholesterol and triglyceride levels and increases lipid accumulation, associated with increased expression of cholesterol synthesis gene HMGCR and altered expression of fatty acid/cholesterol uptake genes (PCSK9, PLTP, CD36) and decreased triglyceride hydrolysis genes (APOC2, APOA4, LIPG, LIPA); MORC4 overexpression reverses these effects, identifying MORC4 as a regulator of hepatic lipid metabolism.\",\n      \"method\": \"siRNA knockdown and overexpression in hepatocytes, TC/TG measurement, lipid accumulation assay, gene expression analysis; in vivo Morc4 knockout mouse data from IMPC database\",\n      \"journal\": \"Frontiers in cardiovascular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function experiments with defined metabolic phenotypes and gene expression readouts, single lab\",\n      \"pmids\": [\"40606021\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MORC4 is a nuclear chromatin-associated ATPase whose activity is activated by cooperative DNA-binding via its ATPase and CW domains; it binds nucleosome core particles to enhance DNA wrapping and impede transcription factor access, forms nuclear bodies, promotes S-phase progression, interacts with STAT3 to transcriptionally activate MID2, interacts with PCGF1 to repress CDKN1A, is targeted for proteasomal degradation by the E3 ligase HECW2, is post-transcriptionally repressed by miR-193b-3p and miR-338-3p, and regulates hepatic lipid metabolism including cholesterol and triglyceride homeostasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MORC4 is a nuclear, chromatin-associated ATPase that modulates nucleosome architecture and gene accessibility [#0, #7]. Its ATPase activity depends on cooperative DNA binding by both its ATPase domain and its CW zinc-finger domain, which together engage the nucleosome core particle to enhance DNA wrapping around the histone core and impede access of DNA-binding proteins such as transcription factors [#0]. In cells, both the CW domain and catalytic ATPase activity are required for MORC4 to form nuclear bodies and to support S-phase progression [#1]. MORC4 also engages specific transcriptional partners to shape gene expression: it interacts with STAT3 to activate transcription of MID2 through STAT3 sites in the MID2 promoter [#2], and it physically associates with the repressor PCGF1 to augment repression of the cell-cycle inhibitor CDKN1A, promoting proliferation [#3]. MORC4 protein abundance is controlled at multiple levels — by proteasomal degradation through the E3 ligase HECW2 [#4] and by post-transcriptional repression via miR-193b-3p and miR-338-3p binding its 3' UTR [#5, #6]. Beyond the nucleus, loss-of-function and gain-of-function studies in hepatocytes identify MORC4 as a regulator of hepatic lipid metabolism, controlling cholesterol and triglyceride homeostasis and the expression of lipid synthesis, uptake, and hydrolysis genes [#8].\",\n  \"teleology\": [\n    {\n      \"year\": 2007,\n      \"claim\": \"Established the domain architecture predicting MORC4 as a nuclear chromatin-associated protein, providing the structural rationale that later biochemical work would test.\",\n      \"evidence\": \"Protein domain annotation and antibody detection in DLBCL patient samples\",\n      \"pmids\": [\"17608765\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Domain annotation without functional validation\", \"No direct biochemical or cellular assay of any predicted activity\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Showed MORC4 abundance is post-transcriptionally controlled by a miRNA and that this loop is functionally consequential for cancer cell survival, answering how MORC4 levels are tuned.\",\n      \"evidence\": \"Dual-luciferase 3' UTR reporter, miRNA overexpression, and siRNA knockdown in breast cancer cells\",\n      \"pmids\": [\"30320920\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking MORC4 level to apoptosis not defined\", \"Single cancer context\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Confirmed a second miRNA (miR-338-3p) directly targets MORC4 and that MORC4 mediates its phenotypic effects, reinforcing miRNA-based control of MORC4.\",\n      \"evidence\": \"Luciferase reporter, RNA immunoprecipitation, and rescue experiments in breast cancer cells\",\n      \"pmids\": [\"31908485\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream molecular pathway from MORC4 to migration/invasion unresolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined the core biochemical mechanism: how MORC4 ATPase activity is activated and how the protein remodels nucleosome accessibility, the central molecular function question.\",\n      \"evidence\": \"Crystal structure of the ATPase-CW cassette plus ATPase assays, mutagenesis, and nucleosome core particle binding assays\",\n      \"pmids\": [\"33122719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Genomic targets of nucleosome engagement in vivo not mapped\", \"Connection between in vitro NCP binding and specific gene programs not established\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Linked MORC4 catalytic and CW-domain functions to cellular outcomes (nuclear body formation, S-phase progression), connecting biochemistry to cell physiology.\",\n      \"evidence\": \"CW and catalytic mutant cell-based assays, nuclear body imaging, cell cycle analysis\",\n      \"pmids\": [\"33122719\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Composition and function of MORC4 nuclear bodies undefined\", \"Mechanism linking ATPase activity to S-phase progression unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified a sequence-specific transcriptional output: MORC4 cooperates with STAT3 to activate MID2, showing MORC4 can promote gene expression in a partner-dependent manner.\",\n      \"evidence\": \"Reciprocal Co-IP, ChIP-qPCR, dual-luciferase reporter, knockdown/overexpression in breast cancer cells\",\n      \"pmids\": [\"32764967\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether activation requires MORC4 ATPase/chromatin activity not tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a repressive transcriptional role via PCGF1, showing MORC4 acts as a cofactor that augments repression of CDKN1A rather than repressing it alone.\",\n      \"evidence\": \"Co-IP, PCGF1 knockdown, overexpression, in vitro and in vivo tumor assays\",\n      \"pmids\": [\"36932196\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct chromatin occupancy at CDKN1A not shown\", \"Single Co-IP for interaction\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified HECW2 as the E3 ligase targeting MORC4 for proteasomal degradation, defining a protein-stability control point.\",\n      \"evidence\": \"Co-IP and proteasome inhibitor experiments (inferred from abstract)\",\n      \"pmids\": [\"36932196\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Limited mechanistic detail from abstract\", \"Ubiquitination sites and conditions regulating degradation not defined\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Extended MORC4 function beyond cancer to hepatic lipid metabolism, showing it regulates cholesterol/triglyceride homeostasis and lipid gene expression.\",\n      \"evidence\": \"siRNA knockdown and overexpression in hepatocytes, TC/TG and lipid accumulation assays, gene expression analysis, IMPC knockout mouse data\",\n      \"pmids\": [\"40606021\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether metabolic effects are direct chromatin-mediated transcriptional regulation not established\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How MORC4's in vitro nucleosome-remodeling and ATPase activity connects to its specific transcriptional partnerships (STAT3, PCGF1) and metabolic functions remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genome-wide map of MORC4 chromatin occupancy\", \"Unknown whether catalytic activity is required for partner-specific transcriptional outputs\", \"Composition of MORC4 nuclear bodies undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [1, 7]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 3]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"STAT3\", \"PCGF1\", \"HECW2\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}